Breaking News Instant updates and real-time market news.

AAPL

Apple

$267.23

-0.64 (-0.24%)

, FCX

Freeport McMoRan

$11.39

-0.23 (-1.98%)

08:55
12/02/19
12/02
08:55
12/02/19
08:55

Notable open interest changes for December 2nd

Friday's total option volume of 10.7 million contracts resulted in net open interest growth of 1.51 million calls and 1.65 million puts. Apple (AAPL), Freeport McMoRan (FCX), Advanced Micro (AMD) and Alibaba (BABA) saw the greatest growth. Top five new positions opened include 13k Freeport McMoRan (FCX) 12/6 weekly 10.5 puts, 12k BP (BP) Dec-19 37.5 calls, 9655 Freeport McMoRan (FCX) 12/13 weekly 10 puts, 8748 Danaher (DHR) Dec-19 170 puts and 8263 Danaher (DHR) Dec-19 170 calls.

AAPL

Apple

$267.23

-0.64 (-0.24%)

FCX

Freeport McMoRan

$11.39

-0.23 (-1.98%)

AMD

AMD

$39.14

-0.25 (-0.63%)

BABA

Alibaba

$199.70

-1.2 (-0.60%)

  • 02

    Dec

  • 09

    Dec

  • 12

    Dec

AAPL Apple
$267.23

-0.64 (-0.24%)

11/19/19
WEDB
11/19/19
NO CHANGE
Target $325
WEDB
Outperform
China the 'linchpin' of success on Apple iPhone supply chain, says Wedbush
Wedbush analyst Daniel Ives tells investors in a research note that President Trump is expected to visit Apple's tech manufacturing facility in Austin, Texas along with CEO Tim Cook in what he calls a key strategic visit for the company. While Ives says he sees more AI and hardware manufacturing coming out of the U.S., India, and potentially Vietnam down the road, for the foreseeable future China remains the "linchpin" of success on the iPhone supply chain with Cook needing to "play nice in the sandbox" both in the U.S. as well as in China to make sure no new roadblocks appear that could derail this potential "5G super cycle" heading into 2020. He keeps an Outperform rating and $325 price target on Apple shares.
11/19/19
FBCO
11/19/19
NO CHANGE
Target $221
FBCO
Neutral
Apple's iPhone unit trends remain 'solid,' says Credit Suisse
Credit Suisse analyst Matthew Cabral tells investors in a research note that nearly two months into the iPhone 11 cycle, data points continue to suggest a meaningful improvement in units y/y. Government data suggests iPhone units are up 6% y/y in China over September and October combined, with Cabal adding that his firm's tracking data suggesting the iPhone has yet to hit full supply/demand balance eight weeks post-launch. While Cabral says he is "on board" with the idea that the shift toward Services deserves a higher multiple over time, he "struggles" with continued P/E expansion seemingly led by firming iPhone data points rather than Services-driven upside. The analyst keeps a Neutral rating and $221 price target on Apple shares.
12/02/19
JPMS
12/02/19
NO CHANGE
Target $296
JPMS
Overweight
Apple price target raised to $296 from $290 at JPMorgan
JPMorgan analyst Samik Chatterjee raised his price target for Apple to $296 from $290 and keeps an Overweight rating on the shares. Early visibility into 2020/2021 iPhone product cycles are offering incremental reasons to be positive relative to volume implications, Chatterjee tells investors in a research note. The analyst, who also raised his volume forecasts and earnings estimates, believes Apple's four new 5G iPhones in the second half of 2020 will offer broader optionality to customers. His supply chain checks indicate that Apple is likely to launch four new iPhone models in September 2020, including all four with 5G capabilities, but only two with ToF World-facing 3D Sensing. Further, the checks indicate that starting 2021, Apple will smooth iPhone seasonality by shortening launch intervals and introducing two new iPhones in both the first half of 2021 and the second half.
12/02/19
WEDB
12/02/19
NO CHANGE
Target $325
WEDB
Outperform
Apple could sell 15M+ AirPods units over the next month, says Wedbush
Wedbush analyst Daniel Ives says that based on Apple store checks, inventory levels and/or shortages at a number of retailers, and reduced prices for AirPods 2, he believes Apple could potentially sell 3M+ AirPod units over the Black Friday/Cyber Monday period. The analyst tells investors in a research note that he is seeing a "surge" of consumer demand for the new AirPods Pro with potential shortages a lingering worry heading into Christmas timeframe. Ives estimates that Apple is on pace to sell over 65M AirPods units in 2019 and is now on a trajectory to potentially reach 85M-90M units in 2020, and thinks Apple will sell roughly 15M+ AirPods globally during the course of the next month. He keeps an Outperform rating and $325 price target on the shares.
FCX Freeport McMoRan
$11.39

-0.23 (-1.98%)

11/07/19
MSCO
11/07/19
INITIATION
Target $21.5
MSCO
Overweight
Teck Resources assumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Carlos De Alba assumed coverage of Teck Resources (TECK) with an Overweight rating and $21.50 price target as part of his assumption of coverage of the NA Metals & Mining industry with an Attractive view. His analysis shows the "unloved" mining sector has outperformed in prior periods of low PMIs and recession risks, the analyst tells investors. He names Teck and Freeport McMoRan (FCX) as his top picks in the space.
11/13/19
BOFA
11/13/19
UPGRADE
Target $14
BOFA
Buy
Freeport McMoRan upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Timna Tanners upgraded Freeport McMoRan to Buy from Neutral with a $14 price target. The analyst is looking past the company's "transition year" and expects its Grasberg asset to make a full contribution for copper and gold production. While copper prices have lagged, Tanners notes that there is support from labor disruptions in Peru and Chile, with added downside protection coming from the still relatively strong CTFC short position.
11/13/19
11/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. G-III Apparel (GIII) upgraded to Buy from Neutral at BofA/Merrill with analyst Heather Balsky saying she anticipates the company to benefit from a likely accelerated wind-down of unprofitable outlet business and derisking with regards to tariffs. 2. Rockwell Automation (ROK) upgraded to Neutral from Underperform at Credit Suisse with analyst John Walsh saying he is upgrading shares based on his view that Industrial Production recovers in 2H20, achievable EPS growth in FY20 driven by restructuring on flat organic sales and a more balanced risk/reward valuation profile. 3. Infinera (INFN) upgraded to Neutral from Underweight at JPMorgan with analyst Samik Chatterjee saying she believes Infinera's recent Coriant acquisition execution is going to make investors more willing to "position themselves for the upside" from the company achieving profitability metrics similar to larger competitor Ciena (CIEN). 4. Freeport McMoRan (FCX) upgraded to Buy from Neutral at BofA/Merrill with analyst Timna Tanners saying she is looking past the company's "transition year" and expects its Grasberg asset to make a full contribution for copper and gold production. 5. Five9 (FIVN) upgraded to Buy from Neutral at Rosenblatt with analyst Ryan Koontz saying he came away from the company's analyst event "thoroughly impressed." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/19
SBSH
11/15/19
NO CHANGE
SBSH
Citi makes Freeport McMoRan top pick in copper, says 'risk-on' winner
Citi's global commodity team highlights copper as their top pick for 2020, analyst Alexander Hacking tells investors in a research note. The analyst says this makes sense given the upside potential if global trade tensions are eased along with cooper's "superior" supply/demand dynamics relative to other base metals. Hacking shifted his top pick to Freeport McMoRan (FCX), which he says offers more leverage to upside in copper. The stock is arguably the most "risk on" exposed stock in Americas mining given its liquidity and beta, Hacking tells investors in a research note. The analyst believes the "gradual de-risking" of Grasberg "appears to be mostly ignored by the market so far." In addition, Southern Copper (SCCO) has been an outperformer year-to-date and "remains a relatively safer, lower beta play," contends Hacking.
AMD AMD
$39.14

-0.25 (-0.63%)

11/21/19
11/21/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. KLA-Tencor (KLAC), Applied Materials (AMAT), and Lam Research (LRCX) were downgraded to Sell from Neutral at UBS. 2. AMD (AMD) downgraded to Market Perform from Outperform at Northland with analyst Gus Richard saying AMD shares are now ahead of the company's fundamentals. 3. Cubic (CUB) downgraded to Neutral from Overweight at JPMorgan with analyst Mark Strouse saying the company reported "mixed" fiscal Q4 results with disappointing EBITDA on stronger than expected revenue. 4. Carnival (CCL) downgraded to Hold from Buy at SunTrust with analyst Charles Scholes citing his analysis of booking trends data, noting that while volumes have improved over the past 8 weeks, the demand is driven by pricing cuts and is targeting mainly the sailings which had been impacted by the September hurricane. 5. MacroGenics (MGNX) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Lebowitz saying based on recent data, he believes that margetuximab might be approvable, but that the drug probably has a limited market opportunity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/21/19
NORL
11/21/19
DOWNGRADE
Target $36
NORL
Market Perform
Northland downgrades AMD, says shares ahead of fundamentals after rally
Northland analyst Gus Richard downgraded AMD (AMD) to Market Perform from Outperform with an unchanged price target of $36. The chipmaker closed Wednesday up 86c to $45.86. AMD shares are now ahead of the company's fundamentals, Richard tells investors in a research note titled "Bull and Bears Make Money, Pigs Get Slaughtered." The analyst says that while the shares "are likely to melt up between now and the end of the year," he would not be chasing them. He expects profit taking in the new year and thinks 2020 will represent a "peak growth year" for AMD. Further, as AMD market share increases, incremental share gains "get much more difficult" due to Intel's (INTC) incumbency, contends Richard.
11/21/19
NORL
11/21/19
DOWNGRADE
Target $36
NORL
Market Perform
AMD downgraded to Market Perform from Outperform at Northland
Northland analyst Gus Richard downgraded AMD to Market Perform from Outperform with a $36 price target.
11/19/19
WELS
11/19/19
NO CHANGE
Target $48
WELS
Outperform
AMD price target raised to $48 from $40 at Wells Fargo
Wells Fargo analyst Aaron Rakers raised his price target for AMD to $48 from $40 after attending Supercomputing 2019, saying the conference provided further confidence in AMD's competitive position. While AMD's current valuation clearly demands upside to current street expectations, Rakers tells investors in a research note that he continues to see AMD's wins in HPC and supercomputing as increasing validation of the company's strong competitive positioning in datacenter CPUs with the 2nd-gen EPYC Rome CPUs and thus remaining supportive of his positive upside thesis. He keeps an Outperform rating on the shares.
BABA Alibaba
$199.70

-1.2 (-0.60%)

11/11/19
RAJA
11/11/19
NO CHANGE
RAJA
Strong Buy
Alibaba Singles Day growth likely beat investor expectations, says Raymond James
Raymond James analyst Aaron Kessler said he believes Alibaba's "solid" 26% year-over-year growth in local currency in Alibaba's Singles Day gross merchandise volume is ahead of investor expectations and leaves him comfortable with his customer management and commission revenues estimate of 86.7B RMB for the December quarter, which will be the company's fiscal third quarter. He reiterates a Strong Buy rating on Alibaba shares and continues to identify the stock as a Top Pick.
11/29/19
BARD
11/29/19
NO CHANGE
BARD
Outperform
Baird still sees 14%+ online spending growth over key holiday shopping season
Baird analyst Colin Sebastian said he remains comfortable with his holiday season e-commerce forecast, saying he still expects "solid" 14%+ online spending growth over the key holiday shopping season, with fewer days between Thanksgiving and Christmas likely benefiting Amazon (AMZN) and traditional retail. The analyst said that overall e-commerce volumes seem to be tracking in line through mid-day of Black Friday, while Thanksgiving Day sales, per Adobe data, were "slightly below" Amazon's forecast, with stronger 17% growth reported by Salesforce.com data. Global e-commerce volume growth is tracking at greater than or equal to 20%, Sebastian added. The analyst also noted that his proprietary tracking of Shopify (SHOP) volumes indicates holiday volumes are up roughly 60% year-over-year, above his total fourth quarter gross merchandise volume growth estimate of about 45%. Sebastian has an Outperform rating on Amazon, Shopify, Alibaba (BABA), eBay (EBAY), and PayPal (PYPL).
11/27/19
HSBC
11/27/19
NO CHANGE
Target $247
HSBC
Buy
HSBC keeps $247 price target on Alibaba after Hong Kong listing
HSBC analyst Binnie Wong maintains a Buy rating on Alibaba with a $247 price target after the company's Hong Kong-listed shares began trading on November 26. The analyst calculates a fair value target price of HK$241 for the Hong Kong shares. She believes Alibaba's revenue growth and sustainable profits are likely to outpace global tech peers.
11/21/19
MACQ
11/21/19
INITIATION
Target $236
MACQ
Outperform
Alibaba initiated with an Outperform at Macquarie
Macquarie initiated coverage of Alibaba with an Outperform rating and $236 price target.

TODAY'S FREE FLY STORIES

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

18:40
12/08/19
12/08
18:40
12/08/19
18:40
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios' initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

18:34
12/08/19
12/08
18:34
12/08/19
18:34
Recommendations
Blueprint Medicines analyst commentary  »

Piper says 'jury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

18:29
12/08/19
12/08
18:29
12/08/19
18:29
Recommendations
Fate Therapeutics analyst commentary  »

FT500 data validates Fate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

18:05
12/08/19
12/08
18:05
12/08/19
18:05
Hot Stocks
Rocket says Phase 1 trial establishes feasibility of commercial Process B for FA »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

ARGX

Argenx

$147.31

-2.56 (-1.71%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

18:03
12/08/19
12/08
18:03
12/08/19
18:03
Recommendations
Argenx, Johnson & Johnson analyst commentary  »

Argenx data on…

ARGX

Argenx

$147.31

-2.56 (-1.71%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 16

    Dec

  • 21

    Jan

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

17:58
12/08/19
12/08
17:58
12/08/19
17:58
Recommendations
Bluebird Bio, Johnson & Johnson, Amgen, Bristol-Myers, Regeneron analyst commentary  »

Piper says…

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

AMGN

Amgen

$233.74

0.3 (0.13%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

REGN

Regeneron

$372.26

4.02 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 21

    Jan

BGNE

BeiGene

$186.89

-2.3 (-1.22%)

17:50
12/08/19
12/08
17:50
12/08/19
17:50
Hot Stocks
BeiGene announces data from two clinical trials of Brukinsa at ASH meeting »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 27

    Feb

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

16:34
12/08/19
12/08
16:34
12/08/19
16:34
Hot Stocks
Eli Lilly presents interim clinical data from LOXO-305 dose escalation trial »

Eli Lilly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 17

    Dec

  • 30

    Jan

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

16:32
12/08/19
12/08
16:32
12/08/19
16:32
Hot Stocks
Bristol-Myers announces data from multiple liso-cel studies at ASH meeting »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

QURE

uniQure

$66.06

1.5 (2.32%)

16:26
12/08/19
12/08
16:26
12/08/19
16:26
Hot Stocks
uniQure reports 1-year follow-up data from etranacogene dezaparvovec study »

uniQure announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

FTSV

Forty Seven

$14.40

0.23 (1.62%)

15:56
12/08/19
12/08
15:56
12/08/19
15:56
Conference/Events
Forty Seven to hold an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AQST

Aquestive Therapeutics

$8.02

-0.34 (-4.07%)

15:50
12/08/19
12/08
15:50
12/08/19
15:50
Conference/Events
Aquestive Therapeutics holds analyst & investor event w/conference call hookup »

Management and Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

APRE

Aprea Therapeutics

$26.20

1.995 (8.24%)

15:23
12/08/19
12/08
15:23
12/08/19
15:23
Conference/Events
Aprea Therapeutics to hold a clinical update meeting »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

15:18
12/08/19
12/08
15:18
12/08/19
15:18
Conference/Events
Blueprint Medicines to hold an anlayst and investor event »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

IFF

International Flavors

$142.03

0.21 (0.15%)

, DD

DuPont

$63.60

1.6 (2.58%)

13:47
12/08/19
12/08
13:47
12/08/19
13:47
Periodicals
International Flavors in talks to buy DuPont nutrition unit, Bloomberg reports »

International Flavors…

IFF

International Flavors

$142.03

0.21 (0.15%)

DD

DuPont

$63.60

1.6 (2.58%)

KRYAY

Kerry Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWRF

China Tower

$0.00

(0.00%)

13:40
12/08/19
12/08
13:40
12/08/19
13:40
Upgrade
China Tower rating change at Deutsche Bank »

China Tower upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

13:37
12/08/19
12/08
13:37
12/08/19
13:37
Recommendations
Principia Biopharma analyst commentary at Stifel »

Principia shares have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$50.93

0.495 (0.98%)

12:48
12/08/19
12/08
12:48
12/08/19
12:48
Syndicate
Dycom withdraws senior notes offering due to market conditions »

Dycom Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

IMV

IMV Inc.

$2.92

0.07 (2.46%)

12:30
12/08/19
12/08
12:30
12/08/19
12:30
Hot Stocks
IMV announces updated results from Phase 2 study of DPX-Survivac »

IMV Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KURA

Kura Oncology

$15.67

0.48 (3.16%)

12:27
12/08/19
12/08
12:27
12/08/19
12:27
Hot Stocks
Kura Oncology announces updates for lead drug candidate tipifarnib »

Kura Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PTLA

Portola Pharmaceuticals

$29.22

0.86 (3.03%)

12:24
12/08/19
12/08
12:24
12/08/19
12:24
Hot Stocks
Portola presents interim results from Phase 2a study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

11:25
12/08/19
12/08
11:25
12/08/19
11:25
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

10:49
12/08/19
12/08
10:49
12/08/19
10:49
Hot Stocks
Fate Therapeutics announces vivo preclinical data for FT596 »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.